随着ADC药物(抗体偶联药物)临床管线持续扩容,其商业化拐点已至,产能缺口进一步凸显。 1月14日,行业龙头药明合联(HK02268,股价 69.100 港元,867.370亿港元)宣布,公司拟以4.000港元/股的价格收购东曜药业(HK01875,股价4.260港元,市值32.920亿港元)股份约7.73亿股。后者是国内最早一批研发抗体偶联药物的企业,近年来转型为CDMO(合同定制研发生产)...
Source Link随着ADC药物(抗体偶联药物)临床管线持续扩容,其商业化拐点已至,产能缺口进一步凸显。 1月14日,行业龙头药明合联(HK02268,股价 69.100 港元,867.370亿港元)宣布,公司拟以4.000港元/股的价格收购东曜药业(HK01875,股价4.260港元,市值32.920亿港元)股份约7.73亿股。后者是国内最早一批研发抗体偶联药物的企业,近年来转型为CDMO(合同定制研发生产)...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.